文献速递膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤前列腺癌

免疫检查点抑制剂在泌尿系统癌症中的系统综述

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
PubMed 文献 · Eur Urol · 2017-06-20

本文系统综述了截至2017年3月16日的随机临床试验,评估免疫检查点抑制剂在晚期转移性尿路上皮细胞癌、肾细胞癌和前列腺癌中的疗效与安全性。在铂类预治疗的尿路上皮细胞癌中,帕博利珠单抗优于化疗;在晚期肾细胞癌中,纳武利尤单抗优于二线依维莫司;在转移性去势抵抗性前列腺癌中,伊匹木单抗未显示优于安慰剂的显著获益。PD-L1表达状态目前不适合作为治疗结局的预测标志物。

要点

  • 铂类预治疗的尿路上皮细胞癌中,帕博利珠单抗较化疗延长中位总生存期并提高客观缓解率。
  • 晚期肾细胞癌中,纳武利尤单抗较二线依维莫司延长中位总生存期并提高客观缓解率。
  • 转移性去势抵抗性前列腺癌中,伊匹木单抗较安慰剂未显示显著获益。

核心结论

  • 在转移性尿路上皮细胞癌和肾细胞癌中,帕博利珠单抗和纳武利尤单抗分别优于二线化疗和依维莫司,疗效和安全性更优。
  • 在前列腺癌患者中未观察到伊匹木单抗的获益效应。
  • PD-L1表达状态目前不适合作为治疗结局的预测标志物。

研究设计与样本

  • 系统综述,检索Medline、Embase和Cochrane Library数据库,截止2017年3月16日。
  • 对随机临床试验(RCT)进行叙述性综述,共纳入6项RCT。

主要发现

  • 在铂类预治疗的尿路上皮细胞癌中,帕博利珠单抗较化疗中位总生存期延长(10.3 vs 7.4个月),客观缓解率更高(21.1% vs 11.4%,p=0.001),不良事件发生率更低(60.9% vs 90.2%)。
  • 三项RCT评估纳武利尤单抗在晚期肾细胞癌中的安全性和疗效,其中位总生存期(25.0 vs 19.6个月)和客观缓解率(25% vs 5%)均高于二线依维莫司,三项研究中纳武利尤单抗安全性良好。
  • 在转移性去势抵抗性前列腺癌中,两项RCT未显示伊匹木单抗较安慰剂有显著获益。
  • 在尿路上皮细胞癌和肾细胞癌中,肿瘤组织PD-L1表达与帕博利珠单抗和纳武利尤单抗治疗期间的临床结局之间无确定性关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: In patients with advanced and metastatic urological cancers, clinical outcome may be improved by immune checkpoint inhibitors (ICIs). OBJECTIVE: To systematically review relevant literature on efficacy and safety of ICIs in patients with advanced and metastatic urothelial cell cancer (UCC), renal cell cancer (RCC), and prostate cancer. EVIDENCE ACQUISITION: Relevant databases, including Medline, Embase, and the Cochrane Library, were searched up to March 16, 2017. A narrative review of randomized clinical trials (RCTs) was performed. EVIDENCE SYNTHESIS: Six RCTs were included for the systematic review. In platinum-pretreated UCC, efficacy of pembrolizumab was superior to chemotherapy, with longer median overall survival (OS; 10.3 vs 7.4 mo), a higher objective response rate (ORR; 21.1% vs 11.4%, p=0.001), and a lower adverse event rate (60.9% vs 90.2%). Three RCTs assessed the safety and efficacy of nivolumab in advanced RCC. The median OS (25.0 vs 19.6 mo) and the ORR (25% vs 5%) were higher in patients treated with nivolumab compared with second-line everolimus. In all three studies, the safety profile of nivolumab was favorable. In patients with metastatic castration-resistant prostate cancer, two RCTs were identified, which did not show significant benefits for ipilimumab over placebo. In UCC and RCC, there was no conclusive association between programmed cell death receptor ligand 1 (PD-L1) expression in tumor tissue and clinical outcome during pembrolizumab and nivolumab treatment, respectively. CONCLUSION: In metastatic UCC and RCC, pembrolizumab and nivolumab have superior efficacy and safety to second-line chemotherapy and everolimus, respectively. No beneficial effect of ipilimumab was observed in prostate cancer patients. PD-L1 expression status is currently not suitable as a predictive marker for treatment outcome. PATIENT SUMMARY: Immune checkpoint inhibitors are able to reactivate the immune system against tumor cells. In second-line setting, pembrolizumab and nivolumab are safe and confer survival benefit in advanced urothelial cell and renal cell cancer, respectively.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Rijnders M, de Wit R, Boormans JL, et al. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. Eur Urol. 2017. PMID: 28645491. doi:10.1016/j.eururo.2017.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。